Dr. Reddy's Laboratories Limited share price
NSE: DRREDDY · BSE: 500124 · ISIN INE089A01031
Key numbers
- Market cap
- ₹ 1,00,042 Cr
- Current price
- ₹ 1,201.00
- 52-week high / low
- ₹ 1,415 / 1,101
- Stock P/E
- 30.2
- Book value
- ₹ 460.3
- Dividend yield
- 0.67%
- ROCE
- 14.0%
- ROE
- 8.8%
- Debt to equity
- 0.21
- Sales growth (3 yrs)
- 11.0%
- Profit growth (3 yrs)
- -1.7%
- 1-year return
- -7.5%
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular,…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 8,545 | 8,805 | 8,727 | 7,516 | 8,071 |
| Operating profit | 2,161 | 2,292 | 1,954 | 641 | 841 |
| Net profit | 1,418 | 1,437 | 1,210 | 221 | 444 |
| EPS (₹) | 17.04 | - | 14.53 | 2.65 | 5.32 |
Concall summary (2026-07-28)
AI summary of the earnings call transcript · tone: Neutral · source document
Guidance & outlook
- And that's what we are saying we will do including the next quarter, which will not be with semaglutide, so that's still the case to be in the neighbo urhood of the 20% .
- But there is a chance that it will fail , I just want to make sure , it's not 100%, but we feel relatively confident.
Growth & demand
- Notably, the underlying base business, excluding lenalidomide, continued to deliver healthy double -digit growth across all key geographies, including North America, supported by new product launches and favourable currency movements.
- IQVIA June 2026 data highlights our continued outperformance of the Indian Pharmaceutical Market (IPM), with moving quarterly total (MQT) growth of 14.6% versus 13.5% for the IPM and moving annual total (MAT) growth of 13.5% versus 11.1% for the market.
Margins & costs
- Consolidated gross profit margin was 46.5%, a decrease of 1,039 basis points YoY and an increase of 169 basis points sequentially.
- The reported gross margin was 51.6% for Global Generics and 4.5% for PSAI.
Capex & expansion
- Capex cash outflow for the quarter stood at ₹307 crores, which is US$32 million.
- Cash flow during the quarter before acquisition related payout was negative ₹216 crores, which is negative US$23 million.
Balance sheet & cash
- As of June 30, 2026, we have a net cash surplus of ₹3,057 crores, i.e., US$323 million.
- Foreign currency cash flow hedges executed through derivative instruments during the period are as follows .
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.